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Summary (260 words): Despite the availability of more than 15 new “antiepileptic drugs”, 
the proportion of pharmacoresistant epilepsy patients has remained constant at about 20-
30%. Furthermore, no disease-modifying treatments shown to prevent the development of 
epilepsy following an initial precipitating brain injury or to reverse established epilepsy have 
been identified to date. This is likely in part due to the polyetiologic nature of epilepsy, which 
in turn requires personalized medicine approaches. Recent advances in imaging, pathology, 
genetics and epigenetics have led to new pathophysiological concepts and the identification 
of monogenic causes of epilepsy. In the context of these advances, the First International 
Symposium on Personalized Translational Epilepsy Research (1st ISymPTER) was held in 
Frankfurt on September 8th 2016 to discuss novel approaches and future perspectives for 
personalized translational research. These included new developments and ideas in a range 
of experimental and clinical areas such as deep phenotyping, quantitative brain imaging, 
EEG/MEG-based analysis of network dysfunction, tissue based translational studies, innate 
immunity mechanisms, mircoRNA as treatment targets, functional characterization of genetic 
variants in human cell models and rodent organotypic slice cultures, personalized treatment 
approaches for monogenic epilepsies, blood-brain-barrier dysfunction, therapeutic focal 
tissue modification, computational modeling for target and biomarker identification, and cost 
analysis in (monogenic) disease and its treatment. This report on the meeting proceedings is 
aimed at stimulating much needed investments of time and resources in personalized 
translational epilepsy research. This Part II includes the experimental and translational 
approaches and a discussion of the future perspectives, while the diagnostic methods, EEG 
network-analysis, biomarkers and personalized treatment approaches were addressed in 
Part I [1] 
Key Words: Treatment targets, Personalized medicine, Precision medicine, Biomarkers, 
New treatment targets 
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Human biopsies and animal models to study mesial temporal lobe epilepsy  
Temporal lobe epilepsy (TLE) is the most common focal seizure disorder in adults. 
Generally, seizures do not start at birth but develop later in life – often after transient insults. 
In many patients, such transient brain insults, including status epilepticus (SE), are followed 
by a latent period of epileptogenesis, preceding the emergence of clinical seizures. 
Mechanisms of epileptogenesis obviously cannot be studied in human brain tissue but 
require the use of animal models (reviewed in [2]). A major component of translational 
epilepsy research addresses the association of pathomechanisms in human epilepsy tissue 
and corresponding animal models. 
In hippocampal biopsies of pharmacoresistant TLE patients, the CA1 pyramidal cell layer 
often shows pronounced neuropathological changes including degeneration and functional 
hyperexcitability. Based on these precedents, we aimed to characterize key 
pathomechanisms that render CA1 pyramidal neurons chronically hyperexcitable after a 
transient brain insult. In a recent study in experimental animals, we demonstrated 
transcriptional upregulation of CaV3.2 T-type Ca2+-channels, resulting in an increased 
propensity for burst discharges of hippocampal CA1 pyramidal neurons, to represent an 
important trigger for epileptogenesis [3]. We further demonstrated that the metal-regulatory 
transcription factor 1 (MTF1) mediates the increase of CaV3.2 mRNA and intrinsic excitability 
consequent to a rise in intracellular Zn2+. Adeno-associated viral (rAAV) transfer of MTF1 into 
murine hippocampi led to increased CaV3.2 mRNA. Conversely, rAAV-mediated expression 
of a dominant-negative MTF1 abolished SE-induced CaV3.2 mRNA upregulation and 
attenuated epileptogenesis. Finally, data from resected human hippocampi surgically treated 
for pharmacoresistant TLE support the Zn2+-MTF1-CaV3.2 cascade to be active also in 
human TLE tissue. As a perspective from ‘bench-to-bedside’, we suggest that 
pharmacological interventions targeting the Zn2+–MTF1–CaV3.2 cascade may provide a 
novel approach for the treatment of pharmacoresistant TLE. 
 
Innate Immunity – Cytokines and Toll-like Receptors in pathophysiology and as 
treatment targets  
Mechanisms of innate immunity play an important role in the development of acquired 
epilepsies. Components of the innate immune system, e.g. cytokines or Toll-like receptors 
(TLRs), can mediate tissue remodelling, leading to network changes that eventually result in 
increased excitation and synchronization, as well as reduced inhibition. In addition, immune 
mediators also have a direct influence on neuronal excitability via post-translational 
modification of ion channels [4,4]. In this respect, interleukin-1 (IL-1) has been studied 
intensely in animal models of epilepsy. Much data from epilepsy models confirmed both pro-
convulsive/pro-epileptogenic actions of IL-1 and protective effects of IL-1 
antagonization/inhibition. Translation of these experimental results to clinical research led to 
the development of a randomized, double-blind phase IIa trial of VX-765, a selective inhibitor 
of IL-1 converting enzyme (ILE) [5]. This study showed a favorable safety profile and a 
reduction of seizure frequency of 8.6% in the treatment group vs. placebo. Surprisingly, a 
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follow-up trial was terminated by the manufacturer. Nevertheless, this trial marked an 
important step towards developing immunomodulatory drugs for epilepsy therapy, potentially 
with disease-modifying activity. 
Translating findings from animal models of epilepsy to the clinic is not a simple process. 
Unpublished data from our group show, for example, opposite regulation of intracellular TLRs 
in two rat models of epilepsy, although both exhibit a very similar phenotype of mesial 
temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS). Such findings highlight the 
need for personalized approaches in both basic research and patient treatment above and 
beyond the current standard, general methods. One helpful tool for personalization is 
cerebral microdialysis. This technique allows repetitive sampling of extracellular molecules at 
consecutive time points within the same individual. Applying a stereotaxic approach, the 
target area can be targeted with extreme precision. We used this technique to establish the 
time course of hippocampal cytokine release in a rat model of mTLE-HS over the course of 
several months (unpublished data). These results will be helpful for precise timing of 
immunomodulatory interventions for epilepsy therapy. In fact, cerebral microdialysis is 
increasingly used as part of multimodal monitoring in humans with severe neurological 
diseases that are often accompanied by status epilepticus. The technique will undoubtedly 
also allow additional insight into the mechanisms responsible for seizures and epilepsy. 
 
MicroRNAs as novel targets in personalized translational epilepsy research  
A fine balance between inhibitory and excitatory synaptic strength is critical for the proper 
functioning of neural networks and therefore a prerequisite for cognition. Defects in the 
inhibitory/excitatory (E/I) balance on the other hand can lead to neurological diseases, such 
as epilepsy. An important mechanism to control excitatory synapse function is homeostatic 
scaling, which regulates synaptic strength in a manner opposite to the stimulus to counteract 
potentially detrimental changes in the E/I balance. Homeostatic downscaling in response to 
chronic overexcitation of networks has been discussed as a pathophysiological mechanism 
in the context of epilepsy, but the underlying gene regulatory programs are little understood.  
One hypothesis is that microRNAs (miRNAs), a large class of small regulatory non-coding 
RNAs, play an important role in the regulation of homeostatic downscaling during epilepsy.  
In previous studies, we have characterized an activity-regulated miRNA, miR-134, that is 
required for the morphological and functional downscaling of excitatory synapses by 
downregulating the RNA-binding protein Pumilio-2 [6]. Intriguingly, inhibition of miR-134 had 
been previously shown to have an anti-epileptogenic function in the kainate epilepsy model 
in mice, suggesting that miRNA-regulated homeostatic plasticity might be a maladaptive 
response during epileptogenesis.  
More recently, we have performed unbiased screening for miRNAs regulated during synaptic 
downscaling in vitro using small RNA sequencing. Thereby, we identified eight miRNAs that 
are upregulated by chronic network activation ([7]. One of these new candidates, miR-129-
5p, was subsequently studied in more detail. Inhibition of miR-129-5p using antisense 
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oligonucleotides interfered with synaptic downscaling in cultured neurons, suggesting that 
miR-129-5p upregulation is necessary for this process. Mir-129-5p expression was 
upregulated in several rodent epilepsy models in vivo and in the hippocampus of human TLE 
patients. Injection of miR-129-5p inhibitors in mice largely abolished kainate-induced epileptic 
seizures, as well as associated increases in neuronal firing rates and hippocampal cell death. 
We further identified two novel miR-129-5p target mRNAs, encoding for the calcium 
extrusion channel Atp2b4 and the microtubule-associated protein Doublecortin (Dcx). 
Overexpression of Atp2b4 and Dcx interfered with synaptic downscaling in cultured neurons, 
suggesting that miR-129-5p mediated downregulation of these proteins is important during 
the scaling response. Moreover, miR-129-5p and Atp2b4 levels were inversely correlated in 
the hippocampus of TLE patients, indicating that the mir-129-5p/Atp2b4 interaction might 
also be relevant in the epileptic brain. Besides regulating Atp2b4 and Dcx, we found that 
miR-129-5p further inhibits expression of synaptic genes by directly targeting the positive 
regulatory RNA-binding protein Rbfox. Therefore, miR-129-5p employs a dual mechanism to 
efficiently inhibit the expression of critical excitatory synaptic proteins during scaling. 
Previous findings regarding increased seizure activity in Rbfox knockout mice are consistent 
with an involvement of the miR-129-5p module in epilepsy ([7]. 
Taken together, our studies suggest an important and widespread contribution of miRNA-
dependent regulation of homeostatic synaptic plasticity to epileptogenesis. miRNAs might 
therefore be used as biomarkers for a precise classification of different types of epilepsy and 
to predict therapy outcome. The knowledge about specific miRNA profiles in epilepsy might 
further inform potential therapeutic strategies that target miRNAs or related pathways.       
 
Isogenic cell models to functionally characterize genetic variants in epilepsy  
In epilepsy, the penetrance of identified genetic variants is often incomplete and the 
functional impact uncharacterized. Therefore, these discoveries are of limited translational 
value. Thus, functional characterization using cost and time efficient model systems is of 
great importance. 
Acknowledging that no model is perfect, we need to weigh between feasibility, effectiveness, 
and translatability of observable phenotypes: Animals have the great advantage to allow 
studying phenotypes at all levels of interest, i.e. molecular, cellular and organismal level. 
However, major limitations are: i) generation of genetically engineered animals for each 
identified variant is not feasible, ii) the non-human background may hamper translatability of 
the phenotype, and iii) the genetic background or noise varies across strains and 
generations. Currently, a good alternative at in-vitro level is using human isogenic neuronal 
cell models. These cell systems allow studying the molecular, cellular and neurophysiological 
effect of a mutation and the respective wild-type gene in the same genetic background. In 
addition, new methods are being developed to study complex cellular interactions at an 
organoid level [8].  
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Isogenic neuronal cell lines can be generated by inducing a mutation into human neuronal 
progenitor cells (HNPCs), or by repairing the respective mutation in patient derived induced 
pluripotent stem cells (iPSCs). Both cell types can then be differentiated into mature neurons. 
Currently, CRISPR/Cas9 technology has proven to be the most effective tool to insert genetic 
modifications at sequence level. This technique allows complete gene-knock-out by insertion 
of premature stop codons as well as precise site directed mutagenesis or gene correction 
within 2-3 months (e.g. correction of SCNA1 mutation in iPSCs [9]), making this system cost 
and time-effective.  
HNPCs, in contrast to iPSCs, are more cost effective and can directly be differentiated into 
neuronal subtypes (i.e. glutamatergic and GABA-ergic or dopaminergic) without any 
intermediate steps. Furthermore, only little intra-individual variation has been reported for 
hNPC in contrast to iPSC derived neurons [10]. However, only iPSCs permit the study of the 
genetic effect within the patient’s specific genetic makeup.  
In summary, CRISPR/Cas9 in combination with iPSC or HNPC cell lines is currently the most 
cost-and time effective alternative to animal models, making them a useful tool to screen for 
the pathogenic effect of a potentially disease causing variant.  
 
Organotypic slice cultures of rodent brains as a tool to study epilepsy  
Organotypic slice cultures of rodent brains have been used for over 25 years to study 
fundamental questions of neuroscience [11]. With the advent of mouse genetics, viral 
transduction techniques, time-lapse imaging and multielectrode array recordings, the 
versatility of these culture preparations has been enormously expanded and they have been 
used singly or in complex preparations to address many biological questions. These 
technological advances have also made it possible to use the organotypic culture technique 
more extensively for disease- and therapy-related research. Thus, organotypic slice cultures 
are now used to (1) study general pathological mechanisms, such as brain 
lesion/regeneration, denervation/collateral sprouting, or neuroinflammation, (2) identify 
specific pathogenetic mechanisms of diseases such as Parkinsons´s disease or Alzheimer´s 
disease, (3) investigate the role of disease genetics, and, (4) test pharmacological and non-
pharmacological therapies (e.g. [12]; [13]; [14]. In short, the organotypic slice culture 
technique has come of age and is now one of the methodological pillars of neuroscientific 
research. 
The use of organotypic slice cultures in the context of epilepsy research is versatile and well-
documented (e.g., [15]). Epilepsy models have been transferred to the in vitro situation using 
organotypic cultures of rat or mouse brain. Seizure-like events can be induced in entorhino-
hippocampal slice cultures using different approaches, e.g., pilocarpin-treatment, changes in 
ion concentrations, or potassium channel blockers. The pattern of damage seen in these 
preparations is similar to the pattern of damage seen in the intact animal. This similarity with 
the in vivo situation opens up many possibilities: Using the modern tools now available to 
study hyperactivity-induced changes directly, e.g. time-lapse imaging, patch-clamp 
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recordings or multielectrode recordings (e.g., [16]; [12]), the role of genetic modifiers and risk 
factors for the course of the disease as well as for its therapy can be elucidated. 
Furthermore, it has been pointed out that these cultures may be particularly effective for 
studying pharmacoresistant seizures and could be used for the identification of new 
antiseizure compounds [17]. Computational approaches complement the battery of 
experimental tools and generate predictions and hypotheses that can in turn be tested in the 
dish. Eventually, however, data obtained using organotypic slice cultures will require in vivo 
verification. Epilepsy is a systems disease and the state of the system as well as its 
functional input and/or output may have major modifying effects in intact animals. Such a 
combined use of in vitro, in vivo (e.g., [18]) and in silico epilepsy models may be used to 
understand the role of modifier genes carried by affected individuals in the context of 
epileptogenesis and may thus contribute to novel personalized therapeutics. 
 
Blood-brain barrier regulation by the Wnt/β-catenin pathway in epilepsy - closing the 
barrier as a potential approach to treat epilepsy  
Endothelial Wnt/β-catenin signalling is necessary for developmental angiogenesis of the 
central nervous system (CNS) and differentiation of the BBB. In the adult Wnt/β-catenin 
maintains BBB characteristics of endothelial cells (ECs) at the neuro-vascular unit (NVU), 
formed by ECs, pericytes, astrocytes, neurons and perivascular microglia. 
Under pathological conditions such as traumatic brain injury, stroke, brain tumor as well as 
Alzheimer’s dementia, the functional homeostasis of the NVU is disturbed, leading to 
increased vascular permeability.  
In the last few years, we and others have shown that Wnt/β-catenin is a master regulator of 
vascular barrier function in the CNS and moreover, we have shown that in glioma, ECs of the 
CNS partially lose their barrier phenotype, indicated by destabilized intercellular junctions 
and down regulated metabolic genes such as ABC transporters and cytochrome P450 
enzymes. The stabilization of β-catenin in glioma ECs resulted in a more quiescent and 
normalized vessel phenotype with reduced permeability, stabilized junctions and increased 
mural cell investment. Preliminary data show that systemic, pharmacological activation of the 
Wnt/β -catenin pathway with an FDA-approved drug can mimic the vascular normalization 
observed in the transgenic mouse models for glioma, suggesting that the Wnt/β-catenin 
pathway might be a promising target for re-sealing the BBB. 
The loss of BBB properties of ECs is also well documented in epilepsy in patients and in 
rodent models. However, if a hampered BBB is the cause or the consequence of SE is 
largely unknown. Interestingly, it has recently been shown that a rare, monogenetic form of 
seizures known as incontinentia pigmenti (Bloch-Sulzberger Syndrome) is primarily caused 
by endothelial apoptosis and barrier dysfunction due to a mutation in IKK/Nemo of the NF-B 
pathway [19]. 
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Although the interaction of the NF-κB and the Wnt/β-catenin pathway has been documented, 
its relevance in ECs and specifically for the etiology and progression of epilepsy is currently 
not known. Additional strong evidence for the involvement of the Wnt/β-catenin pathway and 
the BBB in the occurrence of seizures comes from the recently published adult deletion of β -
catenin specifically in ECs (iCKOEC) of transgenic mice. Induced deletion of β -catenin 
resulted in severe seizures, neuronal injury, haemorrhages and postictal death [20]. 
Based on these striking findings, we hypothesize that endothelial Wnt/β-catenin signaling is 
hampered in SE and that therapeutic activation of the Wnt pathway may counteract the BBB 
loss and hence the initiation and/or progression of the disease. Consequently, we are 
currently investigating the BBB status of SE patients as well as of SE mouse models. 
Furthermore, we will explore the potential benefit of sealing the BBB in epileptic mice via 
Wnt/β-catenin pathway activation in an inducible, conditional -catenin gain-of-function mouse 
model.  
In conclusion, sustained and reinforced Wnt/β-catenin signaling promotes vessel 
stabilization, which might prove to be a valuable therapeutic target for anti-epileptic therapy. 
Nevertheless, further investigation is required to better understand the regulation of the 
Wnt/β-catenin pathway in epilepsy.  
 
Focal tissue modification in personalized translational epilepsy treatment  
Presently, the main strategy for focal modification of brain tissue to treat epilepsy is surgical 
ablation. Although this can be effective (epilepsy surgery can render 70% seizure free), the 
destruction of tissue severely limits this approach, as it is important to avoid eloquent cortex. 
An alternative approach is to modify neuronal excitability, whilst preserving function. In recent 
years, there have been considerable developments in the tools that can help us achieve this. 
In particular, advances in viral vector technology have led to potentially safe and efficacious 
ways of transfecting specific populations of neurons in a focus [21].  
Such gene therapies are an attractive approach to the treatment of neurological disease, as 
they avoid the widespread destruction of epilepsy surgery, but permit specific focal tissue 
modification. We developed and characterized a model of focal motor seizures, which mimics 
epilepsia partialis continua in humans, in order to test the efficacy and safety of our gene 
therapies [22]. This model has a well-defined epileptogenic region in eloquent cortex where 
there are frequent bursts of epileptiform activity that are associated with a focal motor 
phenotype. We took advantage of lentiviral and adeno associated viral vectors which are 
being used in treatment studies of other human disease to transfect excitatory pyramidal 
cells.  
Using a lentivirus vector we overexpressed the potassium channel Kv1.1 in pyramidal cells in 
the focus [22]. This approach reduced the excitability of pyramidal cells without affecting 
motor function. Nevertheless, overexpressing Kv1.1 progressively reduced the epileptiform 
discharges over a period of 20 days as the transgene was expressed [22]. Although the 
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results are very promising, the route to translation is somewhat confounded by gene dose. 
There is a danger that too much Kv1.1 could interfere with function and too little would be 
ineffective.  
We therefore turned to two alternative approaches in which it is possible to titrate the effect 
once the transgene is expressed. First, we used optogenetics, expressing halorhodopsin in 
pyramidal cells [22]. This is a chloride pump that on exposure to yellow/green light pumps 
chloride into the neuron, so hyperpolarizing and decreasing the excitability of the neuron. By 
using different strengths and durations of light, it is possible to regulate the excitability of 
groups of neurons. We transfected pyramidal cells in the focus and placed a fibre optic in the 
focus to deliver light. With this method, we could use the light to decrease the excitability of 
the focus and so decrease seizure activity without interfering with function [22]. Such an 
approach has now been used by others in closed loop devices in which the detection of 
seizure activity activates the light. Although effective, this approach is complicated by having 
not only to target the viral vector to the focus but also to get light into the focus. Moreover, 
halorhodopsin is a foreign protein, raising the concern that it could generate an immune 
reaction, even though the brain is relatively immune privileged.  
Lastly we used a technology termed designer receptors exclusively activated by designer 
drugs (DREADDs). In pyramidal cells in the focus, we expressed a modified “inhibitory” 
muscarinic receptor hM4Di, which is no longer sensitive to acetylcholine, but instead is 
activated by a selective, normally inactive drug clozapine-N-oxide (CNO) [23]. Systemic 
administration of CNO was able to suppress focal seizures evoked by chemoconvulsants 
and also had a robust anti-seizure effect in our model of focal neocortical epilepsy [23]. This 
technology has the advantage of being able to adjust the effect of the gene therapy by 
titrating the dose of drug that specifically activates the receptor. CNO has no other effect 
than on the neurons in which the receptor is expressed, so avoiding systemic and CNS side-
effects. The receptor expressed is a modification of an endogenous receptor, so reducing the 
potential for immunogenicity. DREADDs seem to have many of the characteristics that would 
enable translation into a therapy for human focal epilepsy. 
 
Computational neuroscience to identify treatment targets  
There is a growing interest in how brain circuits are changing during epileptogenesis. Cell 
loss, altered connectivity, and inflammatory responses have all been implicated in 
epileptogenesis, but it’s often unclear which changes are primary causes and which are just 
consequences of other changes. Unraveling these cause and effect relationships is of central 
importance when searching for new treatment methods. The development of computational 
models can be a great tool for understanding such cause and effect relationships, because a 
computational model facilitates a “dissection” of the system and so enables the study of the 
specific role of each component or mechanism for the overall system. Not surprisingly, 
therefore, a number of computational models have investigated how specific structural 
changes to a circuit can make it more prone to exhibit seizure-like activity patterns. This is an 
important first step, but it stops short of answering the harder question of what causes the 
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changes to the structure of these circuits in the first place. We argue that in order to fully 
understand these mechanisms of pathologic circuit changes, it is important to understand 
how these circuits are normally constructed and maintained under basal conditions. 
Remarkably, the structure of cortical and hippocampal circuits is highly dynamic, with new 
synapses constantly being formed and others being removed. Recent computational 
modeling work suggests that the formation and maintenance of brain circuits in the presence 
of this constant turnover of synaptic connectivity can be viewed as a process of self-
organization fuelled by the interaction of a number of plasticity mechanisms, some of which 
are homeostatic [24]. Such models have successfully explained how the distribution and 
fluctuation patterns of synaptic connection strengths are rooted in fundamental plasticity 
mechanisms [25]. The challenge lying ahead is now to investigate what mechanisms could 
be primary causes of the observed circuit changes. The list of candidates is long and none of 
them are mutually exclusive. Aberrant neuronal properties, dysregulated plasticity 
mechanisms, an exhaustion of homeostatic mechanisms, or vicious cycles of neuro-immune 
interactions [26] could all be involved in the process of epileptogenesis. A combination of 
highly detailed, biologically realistic computer modeling [27] and simplified, mathematically 
tractable computational modeling [24,26] is needed to help identify how these mechanisms 
may contribute to epileptogenesis. 
 
Future directions  
Given the fact that the term “epilepsy” refers to a variety of different entities, a high demand 
of personalization in epileptology is obvious. Ultimate goals of personalized translational 
epileptology are 
 to determine the individually contributing patterns of genetic factors and various disease 
mechanisms (e.g. dysregulation of miRNAs, inflammation, blood-brain barrier 
dysfunction) in each single patient, and 
 to tailor specific etiology-related therapies which take account of particular disease 
characteristics in the respective individual (e.g. pharmacogenetics in drug treatment, 
functional anatomy of epileptogenic networks in invasive therapies). 
Tight translational cooperation between basic and clinical researchers is necessary to 
achieve these goals. Hence, future emphasis will be directed to diagnostic methods that can 
be used likewise in both preclinical and clinical research, e.g. new MRI-based techniques or 
cerebral microdialysis. Development and validation of preclinical disease models should be 
addressed more intensely, because selection of valid models for distinct disease entities will 
avoid limitations of research impact on the respective human condition and, therefore, will 
save time, labor and costs. 
Information flow between bench and bedside is bidirectional. Clinical diagnostics and 
resective therapy in epilepsy patients provide the respective electrophysiological data or 
tissue that is required to investigate dysfunction (and, partially, function) of the human brain. 
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Tissue banks are currently established and will become one foundation of interdisciplinary 
multi-method research on disease mechanisms. Thorough phenotyping using advanced 
techniques such as quantitative MRI is a prerequisite for interpreting the results. Analysis of 
EEG data from intracranial recordings will massively profit from the ever-increasing 
computational power and from cooperation between neuroscientists and mathematicians. 
Personalized therapies using new techniques like DREADDs and optogenetics are currently 
still at the preclinical stage. In contrast to resective surgery, these methods offer reversible 
functional inhibition of specific neurons in the epileptogenic zone rather than irreversible 
destruction of brain tissue, and may therefore contribute to a future increase in treatment 
safety. 
Preclinical testing of new therapies is labor-intensive and bears a high risk of failure. For this 
reason, the preclinical development is called “the valley of death” by pharmaceutical 
companies [28]. Concepts and methods of personalized translational research, as described 
above, have the potential to substantially shorten the walk through this unedifying area. 
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